Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. - Wikidata - awgldk - TriplyDB

Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.

Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.

http://www.wikidata.org/entity/Q34254837

about

Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic review Systemic therapies for pancreatic cancer--the role of pharmacogenetics Retrovolution: HIV-driven evolution of cellular genes and improvement of anticancer drug activation The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis.Pancreatic biomarkers: could they be the answer?Role of endoscopic ultrasound in the molecular diagnosis of pancreatic cancer.PharmGKB summary: gemcitabine pathway Finding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: where drug discovery went wrong and how to fix it.A novel method for quantification of gemcitabine and its metabolites 2',2'-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with (19)F NMR spectroscopy.Developments in metastatic pancreatic cancer: is gemcitabine still the standard?Chemotherapy-induced toxicity is highly heritable in Drosophila melanogaster Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine.Pancreatic cancer: why is it so hard to treat?dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma: A Strobe-Compliant Observational Study A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers.Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions.Uptake carriers and oncology drug safety.Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs.Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.Adjuvant pharmacotherapy in the management of elderly patients with pancreatic cancer.Role of solute carrier transporters in pancreatic cancer: a review.Characterization of proteins secreted by pancreatic cancer cells with anticancer drug treatment in vitro.Preoperative therapies for resectable and borderline resectable pancreatic cancer.Heme oxygenase-1 germ line GTn promoter polymorphism is an independent prognosticator of tumor recurrence and survival in pancreatic cancer.Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy.Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma.Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704.Impact of Polymorphic Variations of Gemcitabine Metabolism, DNA Damage Repair, and Drug-Resistance Genes on the Effect of High-Dose Chemotherapy for Relapsed or Refractory Lymphoid Malignancies.Shikonin induces apoptosis and necroptosis in pancreatic cancer via regulating the expression of RIP1/RIP3 and synergizes the activity of gemcitabine.An A/C germline single-nucleotide polymorphism in the TNFAIP3 gene is associated with advanced disease stage and survival in only surgically treated esophageal cancer.Severe acute toxicity following gemcitabine administration: A report of four cases with cytidine deaminase polymorphisms evaluation.Chemotherapy-induced neutropenia as a prognostic factor in patients with metastatic pancreatic cancer treated with gemcitabine.Impact of single nucleotide polymorphisms of cytarabine metabolic genes on drug toxicity in childhood acute lymphoblastic leukemia.Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine.

P2860

Q26767120-51EC29C3-8EC7-47F5-BFD9-09781912FA94 Q26862139-3C70C7F7-ACED-4CA4-8D18-03D05E37B01A Q27021716-F9C0878A-D9A2-4DCA-90B8-39AC99D0AA2F Q28482505-8C206F84-30A8-4EF1-B92B-B70DAF382C48 Q33396763-03B9A7FA-5DFB-4FE0-8EC2-01DB62D5434A Q33801371-0E9AC450-E173-485C-A4EE-2B5242596DEB Q34067856-31687CBE-731F-4E53-8579-49B20DE788EF Q34435450-FD423234-8EDE-4797-9ABB-A4A87DCC7255 Q34646772-FC692797-37BB-481C-B77E-F9C7F543C456 Q35549387-AD193CE7-2071-4AC0-A027-D102B6A07749 Q35776091-BA5152C7-3A5B-46FA-91B3-98FD1C3CE621 Q35830711-09B66CB5-656D-438B-875F-834287FE25FE Q36342657-3C1871F6-6A18-4C3A-A130-F37318979B35 Q36886497-F97531A8-CA1E-4CE8-897F-6BBCF2A17ADA Q37207004-D1EBEFA7-8D4E-4E4E-A1C7-1542F86BE4B5 Q37268613-CA62A9FF-D156-47AA-AAF5-6DB143FD4ED4 Q37342736-4BBD11B9-51D5-44F3-9B5D-F01902850727 Q37663396-94926F64-C1A6-4BB3-9814-7306BCF7FF16 Q37876401-7A42B132-98F7-40B2-9B34-0F8B627FBFA8 Q37994505-F868D7AF-87AF-42BD-9695-A62D127E2EBF Q38075827-67279718-806D-472A-AE7D-6C827D50E361 Q38236028-1E5B17C5-B8EE-4E6D-97B8-18769154A03D Q39282666-54AB861E-D72B-4EC8-956D-623F2FDD7044 Q41836511-73068767-2695-4D63-BF11-7D5FA8772C2A Q42486793-DD04CFF9-102A-4F99-A992-286FDF7D491D Q42725709-30AB0675-2849-402D-9516-49B610B3CD1A Q43829586-A9B7808E-5202-47C7-9C72-8C24F920D9B1 Q44546647-89938019-8657-4B6A-9AB1-42A836F7E6E3 Q47102782-93DF5082-6177-425B-8E41-FF6DA48D0003 Q47377758-785C55E1-FE41-4107-84FA-EE939D971C72 Q48257252-9E8D3578-BF32-41E5-8A8C-21FD7F7AE4A7 Q50053693-4EA75D39-46C6-4DB7-AEEE-AD5920376CE4 Q50659752-E32B0FCC-4DD9-415A-A7FA-8CFB452D431A Q53653257-CE655646-7FA3-40BF-8680-348337177D26 Q54494355-0586E90A-7CA0-4EF3-82E3-234DD1A78728

P2860

Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.

http://www.wikidata.org/entity/Q34254837

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Gemcitabine metabolic and tran ...... ly advanced pancreatic cancer.

@ast

Gemcitabine metabolic and tran ...... ly advanced pancreatic cancer.

@en

Gemcitabine metabolic and tran ...... ly advanced pancreatic cancer.

@nl

type

label

Gemcitabine metabolic and tran ...... ly advanced pancreatic cancer.

@ast

Gemcitabine metabolic and tran ...... ly advanced pancreatic cancer.

@en

Gemcitabine metabolic and tran ...... ly advanced pancreatic cancer.

@nl

prefLabel

Gemcitabine metabolic and tran ...... ly advanced pancreatic cancer.

@ast

Gemcitabine metabolic and tran ...... ly advanced pancreatic cancer.

@en

Gemcitabine metabolic and tran ...... ly advanced pancreatic cancer.

@nl

P1433

Q34254837-445659E1-95D8-4F45-80F0-EDA65800C171

P1476

Q34254837-862FB1A9-51CC-4133-AC27-70DFB1561853

P2093

Q34254837-761BEFF9-4134-4D37-8249-B89E27E93047

Q34254837-7EE5103D-D5B5-4F8B-B3C8-0F887BF54D49

Q34254837-7EE56A91-36A7-46CC-A13D-A50137544EA0

Q34254837-90472BBB-6930-42B1-B1AA-58EC57BBFC7F

Q34254837-B559ECA4-FF57-4E41-A1B7-F0E8851977F8

Q34254837-FF98D59B-D907-4A79-931E-96AE2F9976E7

P2860

Q34254837-06FDC4D8-52D3-458D-99C6-F60C47935A94

Q34254837-0F202D35-8A0E-4CE3-AF4D-1612EF41ECA0

Q34254837-13C43327-6786-4DBC-8740-8E7D8416C618

Q34254837-14F2992F-E1AF-4A6F-8923-3CF8CFAC4973

Q34254837-1A3E4920-8291-4FC7-8EEF-79C56B5BED80

Q34254837-274D4601-74AE-4A48-B9DA-C8E4E015162B

Q34254837-2D336D09-6A54-48F4-B6E3-989F5F1DF06F

Q34254837-33F585AD-7381-45B1-8ABE-45BFFEA4D154

Q34254837-35746F89-CF8F-4C44-8268-EC9978BB927E

Q34254837-3C592155-5940-4750-9CD3-FA5A00E65840

P304

Q34254837-B1EBAB12-200B-4356-879D-82F049D2DE3B

P31

Q34254837-EF433ADC-CDAE-406D-98E3-537220455651

P356

Q34254837-044C76E9-5FA0-4FA4-85C5-7E597CE6406F

P407

Q34254837-A35761A1-36C5-4973-8C4C-3ECCA162D4F0

P433

Q34254837-6E8F19B6-DDFD-4872-B42C-460A239E01D4

P478

Q34254837-359A3D05-114C-4502-B811-A06562ADDE1A

P577

Q34254837-65B82923-C1C3-4FE5-8FC8-6FC1C4680D6F

P5875

Q34254837-0FF39BF9-2DD9-45A7-868D-C555E99070F5

P698

Q34254837-36858CDD-7F90-4331-A14B-C50ECA2C7A6D

P921

Q34254837-02B08F02-E214-403C-83E8-726E8DF64CD4

P932

Q34254837-31F90BE5-B613-4A34-B6C9-65AC03C28B6E

P356

P1433

P1476

Gemcitabine metabolic and tran ...... ly advanced pancreatic cancer.

@en

P2093

Cathy Eng

http://www.w3.org/2001/XMLSchema#string

Donghui Li

http://www.w3.org/2001/XMLSchema#string

James L Abbruzzese

http://www.w3.org/2001/XMLSchema#string

Milind Javle

http://www.w3.org/2001/XMLSchema#string

Motofumi Tanaka

http://www.w3.org/2001/XMLSchema#string

Xiaoqun Dong

http://www.w3.org/2001/XMLSchema#string

P2860

Pancreatic cancer

Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene

Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

Cancer statistics, 2009

Assessing the probability that a positive report is false: an approach for molecular epidemiology studies

A "silent" polymorphism in the MDR1 gene changes substrate specificity

Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells

Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.

Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin.

P304

5325-5335

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.25282

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

116

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45390420

http://www.w3.org/2001/XMLSchema#string

P698

20665488

http://www.w3.org/2001/XMLSchema#string

P921

P932

2966859

http://www.w3.org/2001/XMLSchema#string